Roche extends the tender offer for Spark Therapeutics, Inc.’s shares
By Akshay Kedari  Date: 2019-08-01

Roche extends the tender offer for Spark Therapeutics, Inc.’s shares

The extended tender would provide additional time for the U.S. FTC and U.K. CMA to complete their prior disclosed evaluations of Roche’s acquisition of Spark. 

Swiss healthcare giant, Roche Holding AG have recently announced that it has stretched the offering period of its formerly announced tender offer to purchase all the outstanding shares of common stock of U.S. pharmaceutical company, Spark Therapeutics, Inc. for a reasonable price of $114.50 per share.

According to reliable sources, Citibank, N.A., the depository for the offer, had advised Roche that, as of July 30th, around 9,715,086 shares of Spark had been validly tendered and received, leaving an estimated 25.2% of Spark’s shares as outstanding.

Stockholders who have already given their shares of Spark, do not have to re-tender their shares or take any other action as a result of the extension, suggest reports.

Moreover, closing of the tender offer would depend upon customary closing conditions, including the termination of the valid waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Meanwhile, MacKenzie Partners, Inc., information agent for the offer would request for documents, while questions regarding the offer would be diverted to the company.

For the record, Spark Therapeutics is a startup pharmaceutical company that is focused on developing, discovering and delivering gene therapies. The company aims on developing medicines for genetic diseases, including blindness, lysosomal storage disorders, haemophilia and neurodegenerative diseases.

As for Roche, it is focused on progressing science to improve people’s health. The availability of diagnostics and pharmaceuticals under one roof has helped Roche become a leader in personalized healthcare. The company is also a frontrunner in diabetes management and a global leader in vitro diagnostics and tissue-based cancer diagnostics.

Headquartered in Basel, Switzerland, the Roche Group is spread over 100 countries with a workforce of about 94,000 employees recorded last year. Additionally, in 2018, Roche invested a total of CHF 11 billion in R&D and managed to record a sale of CHF $56.8 billion, cite sources.

Source Credit: https://www.globenewswire.com/news-release/2019/07/31/1894176/0/en/Roche-and-Spark-Therapeutics-Inc-announce-extension-of-tender-offer-for-shares-of-Spark-Therapeutics-Inc.html

 

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Geely Tech to rollout a smart battery swapping network across Jinan
Geely Tech to rollout a smart battery swapping network across Jinan
By Akshay Kedari

Geely Technology Group, a Chinese automobile manufacturer, and the Municipal Government of Jinan, China, have reportedly signed an all-round strategic cooperation deal to jointly develop a network of smart battery swapping service stations across Jin...

CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal
CStone Pharmaceuticals, Pfizer finalize a $200 million share sale deal
By Akshay Kedari

Chinese biotechnology company, CStone Pharmaceuticals has recently announced that it has completed the Share Subscription Agreement with Pfizer Inc. for its newly issued shares worth US$200 million. The move furthers the biotech’s multifaceted ...

Researchers bag $6Mn grant to study the link between Parkinson’s & aging
Researchers bag $6Mn grant to study the link between Parkinson’s & aging
By Akshay Kedari

A three-year grant worth $6 million, funded by the Michael J. Fox Foundation, was recently awarded to a collaborative research team from Michigan’s Van Andel Institute (VAI) and the University of Minnesota Medical School. The grant was given th...

EY announces availability of OpsChain Network Procurement solution
EY announces availability of OpsChain Network Procurement solution
By Akshay Kedari

Ernst & Young (EY), a global professional services network, has recently announced the availability of a first-of-its-kind OpsChain Network Procurement solution. The solution has been built on the company’s OpsChain platform. It will enabl...

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...